Stem cell specialist Ncardia bags new funds to help scale manufacturing ops
A Belgian cell therapy company has secured $60 million in funding to strengthen its manufacturing operations, and grow the cell and gene therapy ecosystem across the world.
Ncardia landed the funding from Kiniciti, a US investment platform backed by Welsh, Carson, Anderson & Stowe, a New York City private equity company. The move gives Kiniciti a controlling stake in Ncardia to enhance anything from discovery to clinical programs to commercialized production, the company said in a press release.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.